Showcasing Pivotal-Stage Clinical Performance of Sigvotatug Vedotin & PDLIV ADCs in Combination with Keytruda For First-Line Thoracic Cancers
- Exploring late-stage clinical data of Sigvotatug vedotin and PDLIV ADCs in combination with Keytruda, highlighting the significance of vedotin ADCs causing immunogenic cell death vs. Topo1 ADCs
- Delving into rationale and synergistic benefit of Keytruda combination approach in thoracic cancers
- Laying out potential for Sigvotatug vedotin and PDLIV combinations to improve thoracic cancer standard of care and impact oncology patientsÂ